Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HK2 | P52789 | 6/20 | 0.53 |
| ▸ | HK1 | P19367 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520981 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15965649 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966250 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966292 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL17210624 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL8930010 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15966273 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL15590477 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL21753475 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL13012256 | 1.00 | KDM4E (0.54) | KDM4ELMNACYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163091-A1 | FUNCTIONALIZED HUMAN MILK OLIGOSACCHARIDES AND METHODS FOR PRODUCING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-22 | — | — | US | claimed |
| CN-113832136-B | Mn-ZIF-90 immobilized Nahk-based composite catalytic material and preparation method and application thereof | 南京师范大学 | 2024-03-26 | — | — | CN | claimed |
| WO-2023141513-A2 | FUNCTIONALIZED HUMAN MILK OLIGOSACCHARIDES AND METHODS FOR PRODUCING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-27 | — | — | WO | claimed |
| WO-2023280235-A1 | HEPARIN MOLECULE CONTAINING AT BINDING SEQUENCE AND CONTINUOUS 2-O-GLUCURONIC ACID RESIDUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东大学 | 2023-01-12 | — | — | WO | claimed |
| CN-114703242-A | Double-enzyme co-immobilization synthesis method of uridine diphosphate-N-acetylglucosamine and derivatives thereof | 山东大学 | 2022-07-05 | — | — | CN | claimed |
| CN-113832136-A | Mn-ZIF-90 immobilized NaHk-based composite catalytic material and preparation method and application thereof | 南京师范大学 | 2021-12-24 | — | — | CN | claimed |
| CN-105452479-B | Reversible heparin molecules | 北卡罗来纳大学查珀尔希尔分校 | 2021-05-18 | — | — | CN | claimed |
| CN-121499684-A | High performance liquid phase analysis method for N-acetyl-glucosamine and N-trifluoroacetyl-glucosamine | 安徽合城生物医药科技有限公司 | 2026-02-10 | — | — | CN | disclosed |
| CN-121499684-A | High performance liquid phase analysis method for N-acetyl-glucosamine and N-trifluoroacetyl-glucosamine | 安徽合城生物医药科技有限公司 | 2026-02-10 | — | — | CN | disclosed |
| US-20250195689-A1 | GLYCOMIMETIC LIGANDS | AVICEDA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2025-06-12 | — | — | US | disclosed |
| CN-116622006-B | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2025-05-30 | — | — | CN | disclosed |
| US-20250163091-A1 | FUNCTIONALIZED HUMAN MILK OLIGOSACCHARIDES AND METHODS FOR PRODUCING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-22 | — | — | US | disclosed |
| CN-114703242-A | Double-enzyme co-immobilization synthesis method of uridine diphosphate-N-acetylglucosamine and derivatives thereof | 山东大学 | 2022-07-05 | — | — | CN | disclosed |
| CN-113832136-A | Mn-ZIF-90 immobilized NaHk-based composite catalytic material and preparation method and application thereof | 南京师范大学 | 2021-12-24 | — | — | CN | disclosed |
| CN-105452479-B | Reversible heparin molecules | 北卡罗来纳大学查珀尔希尔分校 | 2021-05-18 | — | — | CN | disclosed |
| US-7994154-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | Ersai R&D Management Co., Ltd. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-09-09 | — | — | US | disclosed |
| US-7737129-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | EISAI CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | LIPG, FUT6, UGCG | KDM4E 4257/4885LMNA 492/4885CYP2D6 2705/4885 |
| US-20250195689-A1 | GLYCOMIMETIC LIGANDS | SIGLEC9, SIGLEC7, LGALS2 | KDM4E 4635/4885LMNA 3854/4885CYP2D6 3792/4885 |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | LIPG, FUT6, UGCG | KDM4E 4257/4885LMNA 492/4885CYP2D6 2705/4885 |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | HPSE, CD44, CSGALNACT1 | KDM4E 2166/4885LMNA 2836/4885CYP2D6 728/4885 |
| US-20250163091-A1 | FUNCTIONALIZED HUMAN MILK OLIGOSACCHARIDES AND METHODS FOR PRODUCING THEM | GALNT6, GALNT2, GALNT1 | KDM4E 4845/4885LMNA 2180/4885CYP2D6 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.